BACARDI
5.7.2022 13:02:05 CEST | Business Wire | Press release
After decades spent pioneering sustainable practices, MARTINI, the world’s number one Italian sparkling wine and vermouth from family-owned Bacardi, has reached a sustainability milestone – 100% of the wineries for the entire MARTINI portfolio are now certified sustainable.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220705005231/en/
Every drop of grape juice used in the production of MARTINI vermouth and sparkling wines, including MARTINI Fiero and the new MARTINI Non-Alcoholic Aperitivo range, is now sourced from wineries certified according to the standard set by Equalitas, the most comprehensive sustainability standard in Italian wine making.
With the sugarcane for BACARDÍ® rum and the 10 botanicals for BOMBAY SAPPHIRE® already 100% sustainable sourced, this news is another major step towards Bacardi achieving its 2025 goal of sourcing 100% of its key ingredients from sustainably certified suppliers.
Established 160 years ago next year, MARTINI has long pioneered doing the right thing for the environment. In 1987, L'Osservatorio MARTINI – the MARTINI Observatory – was established in Northern Italy as a center dedicated to promoting sustainable farming methods, first for its wines and, more recently, the many botanical ingredients used to craft its iconic vermouths and non-alcoholic aperitivo range.
“It takes a lot of years and a lot of dedication to achieve a milestone like this one,” says MARTINI Master Blender Beppe Musso. “For generations, we have cared for the environment, for our suppliers and for their communities. This certification by Equalitas recognizes the value of those relationships and the value of pioneering sustainable practices.”
Stefano Stefanucci, Director of Equalitas, said: “The scale of what MARTINI has achieved is a first in the Italian wine industry. Equalitas certification is a rigorous process that doesn’t happen overnight so for MARTINI to achieve it across 100% of its wineries is extraordinary.”
Equalitas only works with third-party auditors who are experts with a deep knowledge of the wine sector and the certification process is wholly holistic. Equalitas embraces three sustainability pillars – environmental, ethical and economical – and takes into consideration everything from a winery’s carbon footprint and water consumption through to fair commercial terms for farmers and good social practices including training and welfare.
Victoria Morris, Global VP MARTINI, added: “The care we place on the sourcing of every ingredient is reflected in the quality and taste of every drop of MARTINI. That’s as true for our classic vermouths and sparkling wines as it is for our newest innovation, the fantastic MARTINI Non-Alcoholic Aperitivo range. We are ready to celebrate the 160th anniversary of this iconic brand in style!”
Find out more about the sustainability commitments of Bacardi and its vision to become the most environmentally responsible global spirits company at www.bacardilimited.com/good-spirited .
Always drink responsibly.
About MARTINI
One of the most iconic brands in the world, MARTINI® is the leading name in Italian winemaking and a purveyor of the highest quality aromatized and sparkling wines. The award- winning, vibrant and bittersweet taste of the MARTINI range is the result of secret blends of more than 40 botanicals sourced from the finest locations across the globe. First created in 1863 in Turin, Italy, the MARTINI portfolio today includes: MARTINI Fiero, MARTINI Riserva Speciale Rubino, Ambrato & Bitter, MARTINI Bianco, Rosato, Rosso & Extra Dry, MARTINI Non-Alcoholic Vibrante & Floreale, MARTINI Asti, Prosecco & Rosé Extra Dry. For more information, please visit www.martini.com .
MARTINI and the ball & bar logo are trademarks. MARTINI is part of the portfolio of Bacardi Limited, headquartered in Hamilton, Bermuda. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited.
About Bacardi
Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded 160 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 8,000, operates production facilities in 10 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on Twitter , LinkedIn or Instagram .
About Equalitas
Equalitas is an Italian-born sustainability initiative promoted by Federdoc. Federdoc is the Italian Confederation of Voluntary Consortia for the Protection of the Designations of the Italian Wines. In 2015, Federdoc began several initiatives in the Italian wine value chain including the promotion of one main, certifiable, sustainability standard for companies in the wine sector. Equalitas (the company) is a so called “standard owner”, and it has issued the SOPD Equalitas standard, a set of good practice requirements and sustainability indicators. Through an audit made by third party Certification Bodies, wineries can certify against SOPD Equalitas. Visit www.equalitas.it .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005231/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
